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Abstract
Context—Enhanced Recovery after Surgery (ERAS) programs are multimodal care pathways 
that aim to decrease intra-operative blood loss, decrease postoperative complications, and reduce 
recovery times.
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Objective—To overview the use and key elements of ERAS pathways, and define needs for 
future clinical trials.
Evidence acquisition—A comprehensive systematic MEDLINE search was performed for 
English language reports published before May 2015 using the terms “postoperative period,” 
“postoperative care,” “enhanced recovery after surgery,” “enhanced recovery,” “accelerated 
recovery,” “fast track recovery,” “recovery program,” “recovery pathway”,“ERAS ” , and 
“urology” or “cystectomy” or “urologic surgery.”
Evidence synthesis—We identified 18 eligible articles. Patient counseling, physical 
conditioning, avoiding excessive alcohol and smoking, and good nutrition appeared to protect 
against postoperative complications. Fasting from solid food for only 6 h and perioperative liquid 
– carbohydrate loading up to 2 h prior to surgery appeared to be safe and reduced recovery times. 
Restricted, balanced, and goal-directed fluid replacement is effective when individualized, 
depending on patient morbidity and surgical procedure. Decreased intraoperative blood loss may 
be achieved by several measures. Deep vein thrombosis prophylaxis, antibiotic prophylaxis, and 
thermoregulation were found to help reduce postsurgical complications, as was a multimodal 
approach to postoperative nausea, vomiting, and analgesia. Chewing gum, prokinetic agents, oral 
laxatives, and an early resumption to normal diet appear to aid faster return to normal bowel 
function. Further studies should compare anesthetic protocols, refine analgesia, and evaluate the 
importance of robot-assisted surgery and the need/timing for drains and catheters.
Conclusions—ERAS regimens are multidisciplinary, multimodal pathways that optimize 
postoperative recovery.
Patient summary—This review provides an overview of the use and key elements of Enhanced 
Recovery after Surgery programs, which are multimodal, multidisciplinary care pathways that aim 
to optimize postoperative recovery. Additional conclusions include identifying effective 
procedures within Enhanced Recovery after Surgery programs and defining needs for future 
clinical trials.
Keywords
Enhanced recovery after surgery; ERAS; Perioperative care
1. Introduction
Enhanced recovery after surgery (ERAS) programs are multidisciplinary, multi-element care 
pathways that aim to standardize and improve perioperative management [1]. The goal of 
ERAS is to enable a faster and more efficient recovery using evidence-based practices [1]. 
Studies have shown that ERAS adoption decreases postoperative complications by 50%, 
reduces length of stay (LOS) by 30%, and decreases readmission rates, thereby lowering 
health costs [2]. Cultural and bureaucratic barriers have hindered the adoption of ERAS 
programs in many specialties, including urology. Here, we provide a comprehensive 
overview of evidence-based interventions utilized in ERAS programs. Our aims are to 
determine the effectiveness of specific procedures and to provide a basis for future clinical 
trials.
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2. Evidence acquisition
2.1. Search strategy and study selection
We performed a systematic literature review in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses statement (Fig. 1). We used MEDLINE to 
identify English language articles, reviews, and editorials published prior to May 2015. The 
search terms and selection strategy details are provided in Figure 1. We scrutinized reference 
lists of recovered articles, relevant scientific meeting abstracts, and online guideline websites 
for additional articles. Original articles, publications within the past 5 yr, and those with the 
highest level of evidence were preferred. The quality of evidence from the included studies 
focusing on urological procedures, namely radical cystectomy (RC), was comprehensively 
assessed using the US Agency for Healthcare Research and Quality method (Table 1).
3. Evidence synthesis
The electronic search yielded 956 potential urological articles, of which 50 were assessed 
for eligibility (Fig. 1). Until recently, the published ERAS literature has focused primarily 
on colorectal surgery outcomes. The adoption of ERAS pathways across different surgical 
disciplines has spread informally, although there have been some notable coordinated 
initiatives. For example, the UK National Health Service’s Enhanced Recovery Partnership 
Program acted as a catalyst for adoption among surgical specialties Recently, ERAS 
guidelines have been developed and published for several surgical procedures [1,3,4]. 
Guidelines vary by specialty but include at least 20 elements categorized into preoperative, 
intraoperative, and postoperative components [3].
3.1. Preoperative ERAS elements
3.1.1. Preadmission information and expectation counseling—Written, verbal, or 
electronic counseling about ERAS prior to surgery is important for successful 
implementation and may reduce patient anxiety. Counseling reduces the LOS, recovery time, 
and unplanned community interventions [4]. The patient should be actively engaged by 
preoperatively meeting members of the entire surgical team.
3.1.2. Preoperative optimization—Preoperative assessment is important for patients 
undergoing major surgery. It should identify and optimize risk factors/medical conditions 
that affect recovery. Physical conditioning and muscle training may improve recovery rates 
[3]. Smoking cessation and avoiding excessive alcohol intake for a minimum of 1 mo before 
surgery protects against postoperative complications [4]. However, smoking cessation 
immediately before surgery may cause greater harm than good [4]. Therefore, perioperative 
guidelines recommend that patients stop smoking at least 8 wk before surgery to help 
minimize pulmonary complications that often occur following abrupt smoking cessation by 
long-term smokers [5]. Nevertheless, time is not always available to stop smoking. If the 
patient does stop smoking and has problems with intestinal transit nicotine substitution 
should be considered as well as physiotherapy for the prevention of pneumonia.
Poor nutrition and diet are widely accepted risk factors for surgical morbidity. Currently, the 
most valuable tool for the nutritional screening of surgical patients is the Nutritional Risk 
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Score, which is officially recommended by the European Society of Parenteral and Enteral 
Nutrition with Level 1 evidence validation. The Nutritional Risk Score is based on the 
degree of malnutrition (defined by weight loss, food intake, and body mass index) and 
disease severity (Table 2) [6].
Immuno-enhanced nutrients involve substrates that modulate the host immune system and 
inflammatory response. Randomized clinical trials (RCTs) have demonstrated that 
immunonutrition (a combination of arginine, fish oils, and nucleotides) positively modulates 
postsurgical immunosuppressive/inflammatory responses and host defense mechanisms after 
major surgery, even in well-nourished patients, thereby reducing LOS and infection risk [7]. 
A recent RCT suggested that providing immunonutrient support to RC patients can improve 
immunological defenses and reduce postsurgical infection [7].
3.1.3. Preoperative bowel preparation—The role of mechanical bowel preparation for 
ileocolic or colonic reconstruction requires further evaluation. This process can dehydrate 
patients and cause electrolyte imbalance, physiological stress, and prolonged ileus after 
colonic surgery. A systematic review and meta-analysis of colonic surgery studies concluded 
that there was no advantage of bowel preparation [8]. In contrast, evidence suggests that this 
intervention may be associated with higher rates of anastomotic leakage and incisional 
complications [8].
There is a lack of evidence from large RCTs to support using bowel preparation in RC 
patients, as many physicians have already extrapolated from the colonic surgery literature 
and are actively omitting this practice [9,10].
3.1.4. Preoperative fasting—A Cochrane review of 22 RCTs found that prolonged 
fasting prior to surgery is not necessary [11]. Consequently, most anesthesiologists 
recommend withholding solid food for 6 h and fluids for 2 h before surgery [12]. The 
European Society of Anesthesiology notes that patients who may have delayed gastric 
emptying (eg, obese patients), patients with gastroesophageal reflux, patients with diabetes, 
and pregnant women can also safely adhere to these guidelines [12].
3.1.5. Preoperative carbohydrate loading—Preoperative carbohydrate loading using 
clear electrolyte/carbohydrate-containing liquids helps reduce thirst, and helps maintain lean 
body mass and muscle strength during colorectal surgery [3], thereby decreasing recovery 
times[13]. A meta-analysis of preoperative liquid carbohydrate treatment in open abdominal 
surgery patients revealed a significant reduction in LOS compared with controls (mean 
difference [MD]–1.08 d, 95% confidence interval [CI]–1.87 to −0.29; seven trials; I2 = 60%) 
[13].
Oral and intravenous (IV) modalities are also effective at reducing insulin resistance and 
hyperglycemia [14]. Carbohydrate loading is a standard-of-care technique in ERAS 
programs that is safe in diabetic populations and can be given up to 2 h before surgery [14].
3.1.6. Preoperative alvimopan administration—Alvimopan is a peripherally active μ-
opioid receptor antagonist. The use of alvimopan has been associated with a reduced LOS 
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and faster recovery of bowel function after abdominal surgery and RC [15,16]. In a recent 
RCT of patients undergoing RC, patients were randomized 1:1 to receive either a single dose 
(12 mg) of oral alvimopan or placebo between 30 min and 5 h before surgery and then 
twice-daily oral doses postoperatively until hospital discharge or a maximum of 7 d. The 
alvimopan cohort experienced an earlier first bowel movement (5.5 d vs 6.8 d; hazard ratio: 
1.8; p < 0.0001), shorter mean LOS (7.4 d vs 10.1 d; p = 0.0051), and fewer episodes of 
postoperative ileus-related morbidity (8.4% vs 29.1%; p < 0.001), although there were 
concerns regarding cardiovascular events [16].
The role of alvimopan in patients undergoing urological surgery other than RC must be 
evaluated in future trials (particularly in those undergoing minimal access surgery, who 
typically require less morphine than those undergoing open surgery).
3.1.7. Pre-anesthetic medications—Long-acting benzodiazepines can cause cognitive 
impairment and functional disruptions, particularly in elderly patients, for up to 4-h 
postsurgery, leading to reduced movement, eating, and drinking [3,4]. Short-acting 
benzodiazepines are preferred if necessary to reduce anxiety and facilitate patient 
positioning [3,4].
3.1.8. Prophylaxis against venous thromboembolism—In a landmark study, 
Bergqvist et al [17] observed a significant decrease in the posthospitalization venous 
thromboembolism rate among abdominal and pelvic surgical oncology cases in which low-
molecular-weight heparin prophylaxis was continued for 19–21 d after a standard in-house 
anticoagulation regimen compared with placebo. No RCT or prospective study has 
compared complication rates with and without deep vein thrombosis prophylaxis in RC 
patients. Morbidity rates in these patients remain high due to the high risk of postsurgical 
complications.
Low-molecular-weight heparin drugs are the most tolerable, efficacious, and cost-effective 
drugs in this setting [17]. Other protective measures include the use of intermittent 
pneumatic compression devices and compression stockings during hospitalization [18].
3.1.9. Antimicrobial prophylaxis and skin preparation—Cystectomy patients 
benefit from prophylactic antimicrobial agents, although the best antibiotic regimen is 
unclear and likely depends on local antibiotic-resistance profiles. European Association of 
Urology guidelines recommend preoperative dosing less than 1 h prior to skin incision, 
continuing for up to 24 h and extending to 72 h for patients with specific infection risk 
factors or prolonged operations (>3 h). American Urological Association guidelines 
recommend a second-generation or third-generation cephalosporin or a combination of 
gentamicin and metronidazole for 24-h preoperatively if there are no patient risk factors. 
Several ERAS guidelines recommend skin preparation prior to surgery using a 
chlorhexidine-alcohol scrub to prevent surgical site infections (SSIs) [3,4].
3.1.10. Prevention of intraoperative hypothermia—Avoiding intraoperative 
hypothermia helps protect against perioperative coagulopathy and may reduce LOS [19]. 
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The most effective warming strategies are forced-air warming blankets and warmed IV 
fluids [19].
3.1.11. Anesthetic protocols: systemic and regional anesthesia—The 
administration of intraoperative central or regional neural blockade reduces opioid use and 
may facilitate early enteral feeding and mobility [3]. Thoracic epidural anesthesia is widely 
recommended in open colorectal surgery and reduces LOS and postoperative ileus compared 
with patient-controlled analgesia [3].
Various studies have demonstrated the successful use of epidural anesthesia [20] or patient-
controlled analgesia [21] and rectal sheath catheters [22] in open RCs. No prospective 
studies have compared these anesthetic protocols in RC surgeries.
3.2. Intra-operative ERAS elements
3.2.1. Surgical approach—Surgical approach (ie, open vs minimal access) may 
influence outcomes, complications, and recovery rates. Minimally invasive surgery requires 
smaller incisions, reduces analgesic use, reduces bowel handling, and decreases blood loss 
[23]. As such, laparoscopy may decrease postoperative complications, pain, and LOS 
compared with open surgery [24]. However, it is unclear whether laparoscopic resection 
provides better outcomes than open surgeries performed within ERAS programs.
Robot-assisted surgical approaches are increasingly utilized in urology [23,24], but the exact 
benefit over open surgery remains unclear. Limited evidence suggests similarities in 
oncology and morbidity, with reduced blood loss and analgesic use [23–25], although 
operating times are significantly longer. Procedure-specific RCTs that incorporate cost 
analysis, recovery rates, and quality of life (QoL) outcomes are needed to assess the 
advantages of robotic-assisted laparoscopy [1].
3.2.2. Perioperative fluid management—Fluid management in patients undergoing 
urology surgery can be challenging because urine output is often not measurable 
intraoperatively and requires careful measurement in the postoperative period. Excess fluid 
and hypervolemia lead to splanchnic hypoperfusion and ileus [26]. Within ERAS, both 
restricted and balanced fluid management protocols have been advocated [27]. Regardless, 
careful fluid replacement reduces bleeding, complications, and LOS.
Goal-directed fluid therapy (GDFT) attempts to add precision to fluid resuscitation by 
optimizing perfusion and oxygen delivery (maintaining normal physiological fluid balance 
and homeostasis). GDFT involves intraoperative regimens that use esophageal Doppler 
monitoring to optimize stroke volume [26]. GDFT decreases complication rates and LOS 
among patients undergoing colorectal surgery [26]. However, these studies evaluated GDFT 
against standard fluid management techniques, and the comparison groups often had fluid 
overload or unwarranted restrictions. Studies have also indicated that GDFT reduces 
postoperative nausea and vomiting (PONV) [26]. Restrictive intraoperative hydration 
combined with norepinephrine administration reduces intraoperative blood loss (and 
therefore transfusions), postoperative complications, and, consequently, LOS in open RCs 
[28].
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Prospective studies are needed to compare restricted, balanced, and GDFT in patients 
undergoing urological surgery. The benefits of GDFT may be less significant when 
comparing GDFT to restrictive or balanced fluid techniques as opposed to balanced 
crystalloids. Additionally, the benefits of GDFT may be more individualized and more 
strongly influenced by patient surgical and medical risk factors.
3.2.3. Nasogastric intubation—Avoidance or early removal of a nasogastric tube (NGT) 
is recommended. Although most data are associated with colorectal surgery, numerous 
reports suggest relevance to urological procedures [29]. The use of NGTs in colonic surgery 
has decreased from 88% to 10%, without an increase in complications or an effect on major 
outcomes (bowel recovery, LOS, and morbidity) [30]. A meta-analysis of more than 33 
RCTs demonstrated that avoiding NGTs decreases postoperative complication rates and the 
time to return of normal bowel function after abdominal surgery [30]. Lower rates of 
pharyngolaryngitis, respiratory infections, and vomiting have also been observed when 
NGTs are avoided [30]. Therefore, nasogastric suction may be limited to cases of prolonged 
postoperative ileus.
3.2.4. Urinary drainage—One study investigated the effect of time-to-stent removal in 
ileal bladder substitute and ileal conduit patients [31]. The study compared patients whose 
stents were removed directly following ureteroileal anastomosis with those whose stents 
were removed 5–10 d after surgery. Stenting improved drainage in the upper urinary tract, 
accelerated bowel recovery, and decreased the rate of metabolic acidosis [31]. The optimal 
duration of ureteral stenting must be further investigated to make safe recommendations.
3.2.5. Pelvic drainage—Studies have shown comparable outcomes in colorectal surgery 
patients with or without peritoneal cavity suction drains for anastomotic leaks [3], 
suggesting that these drains are not necessary. However, these results may not be applicable 
to cystectomy patients because of the possible risks of urinary leakage following surgery [1]. 
Postsurgical drains at the incision site significantly reduce the risk of SSI and LOS [31]. 
Different ERAS protocols have suggested that pelvic drains be removed as soon as possible; 
however, there is no clear evidence for the optimal time for removal to reduce SSI risk [32–
34].
A new closing method using subcutaneous continuous aspiration drains has been associated 
with a reduced SSI rate after RC [35]. This method combines a dermal suture with a 
subcutaneous drain with a wide suction area to help reduce pressure and damage to 
surrounding areas during recovery.
Recently, a RCT reported that re-approximation of the dorsolateral peritoneal layer 
following extended pelvic lymph node dissection and cystectomy improves postoperative 
recovery of bowel function with less postoperative pain and fewer complications [36].
3.3. Postoperative ERAS elements
3.3.1. Postoperative nausea and vomiting—PONV are the most commonly reported 
adverse events after surgery (25–35% of surgical patients), the most cited reasons for patient 
dissatisfaction, and the primary reasons for increased LOS. PONV contribute to pulmonary 
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aspiration and increased bleeding (through straining). The use of inhalation anesthetics, 
nitrous oxide, and opioids during surgery increases the likelihood of PONV [1]. PONV can 
be reduced or minimized by administering multimodal antiemetic prophylaxis with agents 
such as ondansetron [37]. Dexamethasone is also safe, efficacious, and inexpensive for such 
prophylaxis [37]. Combining the use of nitrous oxide and propofol also reduces PONV, and 
no significant interactions between these medications have been observed [37]. These 
medications are most effective when used as prophylaxis. Such prophylaxis can improve 
patient satisfaction, decrease recovery times, decrease LOS, and reduce the frequency of 
hospital readmission. One RCT found that intervention with intraoperative fluid 
optimization using esophageal Doppler monitoring of cardiovascular volumes significantly 
reduced PONV at 24 h and 48 h post-RC surgery [38]. A small study of 54 patients noted 
that the PONV rate was reduced by stenting of the ureteroileal anastomosis [31].
3.3.2. Ileus prophylaxis and use of postoperative laxatives—Ileus is a common 
event following RC that may also occur following prostatectomy and renal surgery. ERAS 
pathways highlight the importance of preventing postoperative ileus [1,4]. Prokinetic agents, 
such as metoclopramide, were traditionally advocated for use within ERAS programs to 
reduce the incidence of postoperative ileus. Although metoclopramide may not alter the 
time-to-first flatus or bowel opening, this agent appears to reduce PONV [39]. Gum chewing 
appears to be beneficial for abdominal and gastrointestinal surgery patients [35,40]. Various 
trials have systemically evaluated the effect of gum chewing on patient outcomes after 
cystectomies or gastrointestinal surgeries [35,39,40]. A recent meta-analysis found 
significant reductions in time to first flatus (weighted MD −12.6 h, 95% CI −21.49 to −3.72; 
eight arms) and to first bowel movement (weighted MD −23.11 h, 95% CI −34.32 to −11.91; 
seven arms) among patients who chewed gum compared with controls [40]. This effect was 
mediated by a reduction in postoperative paralytic ileus following gastrointestinal surgery in 
patients who chewed gum. Despite these findings, there was no significant difference in LOS 
between patients who chewed gum and controls.
Prophylactic oral laxatives have been recommended after surgery, and they are associated 
with an earlier return to normal bowel function and a reduction in time to defecation 
[3,4,41]. No prospective studies have systematically evaluated the benefits of oral laxatives 
in rectal or urological surgery with or without the use of ERAS pathways; such studies are 
necessary to ascertain the effects on patient outcomes, such as anastomotic dehiscence.
3.3.3. Early feeding—Resuming normal food intake as soon as possible following surgery 
is recommended. Early feeding (within 24-h postsurgery) was traditionally thought to 
increase the risk of bowel complications, but studies of patients who underwent 
gastrointestinal surgery have demonstrated positive effects on many outcomes (eg, insulin 
resistance, muscle function, wound healing, and risk of sepsis) [42]. A meta-analysis of 
major abdominal surgery patients revealed a significantly lower incidence of anastomotic 
dehiscence, pneumonia, and mortality among patients who ate early following surgery [42]. 
The benefits of early oral intake after major abdominal surgery include decreased paralytic 
ileus, fewer infectious complications, and a faster recovery. These benefits have been 
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demonstrated in patients who underwent primary bowel anastomoses, with similar results to 
those who underwent cystectomy and urinary diversion [42].
However, vomiting is a risk of early postoperative oral intake. Active interventions for 
PONV must be instituted alongside early oral intake. All ERAS protocols incorporate active 
measures to manage nausea and reduce postoperativeileus, including sched uled antiemetics, 
chewing gum, cholinergic stimulants, laxatives, prokinetic agents, and limitations on 
narcotic administration.
Total parenteral nutrition is not routinely given to patients unless a delay in substantive 
enteral nutrition of greaterthan 5–7 d is expected following surgery. Given the risks of 
parenteral nutritionand the lack of any benefit in patients for short periods of time, total 
parenteral nutritionis also not initiated in any patient for whom less than 7 d of treatment is 
expected[ 43]. Nutritional assessments may help selectthose patients who are best suited for 
pre-and postoperative nutritional interventions.
Current data do not support the routine use of parenteral nutrition, and there are limited data 
on urological patients, particularly those undergoing cystectomy. Urinary spillage, uretero–
enteric anastomosis, and large pelvic and retroperitoneal dissection differ between urological 
and colonic surgery; therefore, these data may not be directly comparable.
3.3.4. Postoperative analgesia—Appropriate analgesia facilitates early postoperative 
mobility, which in turn may counteract insulin resistance, reduce thromboembolic events and 
chest infection rates, increase muscle strength, and possibly reduce ileus [1,3]. Multimodal 
opioid-sparing analgesia, combined with regional or local anesthesia, is recommended [1] 
and aims to provide effective pain management while minimizing the side effects of opioids. 
Xu et al [44] observed that patients on an ERAS protocol (opioid-sparing analgesics) used 
significantly less opioid analgesics after RC.
Typically, thoracic epidural analgesia with wound infiltration or rectus sheath cannulas is 
used 24-h and 72-h postsurgery [48] in combination with systemic analgesics and patient-
controlled opioid delivery.
Oral or IV paracetamol and/or nonsteroidal anti-inflammatory drugs have typically been 
used in cystectomy [20–22]. RCTs are needed to compare the effects of these pain 
medications on cystectomy patients. The use of adjunct medications, such as gabapentin, 
requires further evaluation [4].
3.3.5. Early postoperative mobilization—Early postoperative mobilization may have 
benefits, as previously mentioned, including counteracting insulin resistance and reducing 
chest complications. It can reduce pain and the likelihood of developing ileus, therefore 
hastening functional recovery [43]. RCTs are needed to evaluate the types and rates of 
improved outcomes for urological patients.
3.3.6. Discharge criteria—ERAS programs recommend that discharge should only occur 
when patients have resumed adequate oral intake and normal bowel function with effective 
oral pain management and when no other clinical or biochemical concerns remain, including 
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stoma or neobladder competency. Patients should be well supported with regular telephone 
follow-ups by clinicians and access to an emergency phone number [21].
3.4. System data in ERAS
3.4.1. Audit—Auditing is an essential component of evaluating and improving the quality 
of healthcare practices and systems. Auditing ERAS programs can help assess compliance 
with recommended pathways, which is necessary to ensure successful implementation and 
evaluate the effect on clinical and financial outcomes [14]. Auditing can also help ensure 
that ERAS programs continue to be as dynamic as possible by adapting pathways that 
enable the development of individualized guidelines specific to different surgical modalities, 
disease states, or institutions [14].
3.5. Outcomes of ERAS
3.5.1. Postoperative recovery and length of stay—ERAS programs aim to improve 
patient recovery; however, there is no universally accepted definition of “recovery,” which 
encompasses multiple physiological parameters and thus complicates the evaluation of 
ERAS effectiveness. A systematic review of 38 studies of major elective abdominal 
surgeries concluded that the most commonly reported outcome measure of recovery within 
ERAS programs was LOS [45]. A recent trial provided clear evidence that ERAS programs 
in urological surgeries significantly shortened LOS after RC and urinary diversion, without 
increasing the hospital readmission rate [22]. In the ERAS arm of 126 patients, 82% had a 
bowel movement by 2-d postoperative, the median LOS was 4 d, and the 30-d readmission 
rate was 21% [22]. A recent prospective, randomized study compared outcomes after RC 
across patients treated within and outside ERAS protocols [46]. This study identified lower 
morbidity (fevers, wound healing disorders, and thrombosis), less demand for analgesics, 
less time spent in intermediate care, and higher physical and emotional QoL scores in the 
ERAS group compared with controls [46]. Table 3 summarizes the main outcomes of ERAS 
studies in the urological literature.
3.5.2. Cost effectiveness—Few studies have evaluated the cost effectiveness of ERAS 
programs. A meta-analysis of RCTs in colorectal surgery in the US indicated a mean savings 
of $2000 per patient treated under ERAS [2].
One of the major criticisms of ERAS is that because patients are discharged from the 
hospital earlier, they may represent more frequently to the hospital after discharge. One 
prospective study evaluated the readmission rate among cystectomy patients and found no 
significant difference between the ERAS and control groups (21% vs 18%, p = 0.1); this 
readmission rate was comparable to that for other large centers [22].
Overall, ERAS protocols appear to be clinically efficacious and cost effective. However, 
randomized prospective studies to systematically evaluate cost-savings data (both in-hospital 
and out-of-hospital costs) for urological surgeries are lacking, and further work is needed to 
ensure that both the short-term and long-term cost savings of ERAS programs can be 
effectively captured and assessed.
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3.5.3. QoL—Various authors have examined the impact of ERAS on QoL [46,47]. One 
study observed no improvements in QoL between ERAS and standard care [47], whereas the 
other study observed a nonsignificant trend in improved QoL after ERAS adoption [46]. The 
tools used within these studies may not have been sufficiently sensitive to detect 
improvements in recovery as noted by clinicians.
3.6. Adherence to ERAS protocols and barriers to implementing ERAS programs
Despite increasing evidence for the safety, potential cost savings, and improved outcomes of 
ERAS, institutions, surgeons, and clinicians have been slow to adopt ERAS programs. 
Replacing and/or adapting existing protocols and standard operating procedures can take 
many years, and decision makers require evidence of efficacy. One limiting factor in 
adoption is that much of the existing supporting evidence for ERAS has come from small-
scale retrospective studies. Larger, prospective studies are necessary to provide clearer, 
stronger evidence for the need for and value of ERAS programs at existing institutions. 
Notably, the rate of adverse postoperative outcomes is directly related to percent adherence 
to ERAS components. Some researchers have recommended processes to facilitate ERAS 
adoption and adherence to ERAS elements. The successful implementation of an ERAS 
program requires full commitment and support of the involved parties.
4. Conclusions
4.1. Future perspectives and research initiatives in fast-track surgery
The major paradigms underlying ERAS protocols, while focused primarily on clinical 
recovery from surgery, also feature significant interplay with health economics, as described 
above. Future perspectives on ERAS will rely on additional data collection on the impact of 
ERAS from the patient’s perspective and on costs after hospitalization.
Out-of-hospital costs are often not considered in cost-effectiveness analyses of ERAS 
protocols. The focus is primarily on direct hospital-related care costs during initial 
hospitalization. However, postoperative communication, follow-up, and long-term 
complications require additional resources to prevent readmissions and enhance patient 
comfort and QoL. These costs and those associated with readmissions should be considered 
in future evaluations to better clarify the overall costs associated with patient care.
A final future perspective reemphasizes one of the core principles behind successful ERAS 
protocols: collaboration between surgery and anesthesia, which is essential to both the 
implementation of an ERAS protocol and its long-term stability and effectiveness. Evolving 
research is focusing on reducing opioid reliance, decreasing postoperative ileus, and 
optimizing or implementing GDFT management and catheterization.
As noted earlier, ERAS programs for cystectomy have been largely extrapolated from 
colorectal studies [1]. Given the oncological, procedural (small bowel anastomosis and urine 
within the peritoneal cavity), and morbidity differences between colorectal and cystectomy 
surgery, there is an urgent need to evaluate ERAS pathways in patients undergoing 
urological surgery, specifically cystectomy.
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Although there is accumulating evidence supporting the use of ERAS pathways in 
cystectomy patients, most studies are retrospective or underpowered. Thus, high-quality 
prospective multicenter studies are needed to assess the different elements of ERAS 
protocols, such as optimal perioperative nutritional support, as well as the type and duration 
of pelvic and urinary catheterization, and the need to tailor ERAS elements in open- versus 
minimally-invasive surgery.
Acknowledgments
Funding/Support and role of the sponsor: None.
References
1. Patel HR, Cerantola Y, Valerio M, et al. Enhanced recovery after surgery: are we ready, and can we 
afford not to implement these pathways for patients undergoing radical cystectomy? Eur Urol. 2014; 
65:263–6. [PubMed: 24183418] 
2. Lemanu DP, Singh PP, Stowers MD, Hill AG. A systematic review to assess cost effectiveness of 
enhanced recovery after surgery programs in colorectal surgery. Colorectal Dis. 2014; 16:338–46. 
[PubMed: 24283942] 
3. Nygren J, Thacker J, Carli F, et al. Guidelines for perioperative care in elective rectal/pelvic surgery: 
enhanced recovery after surgery (ERAS) Society recommendations. Clin Nutr. 2012; 31:801–16. 
[PubMed: 23062720] 
4. Cerantola Y, Valerio M, Persson B, et al. Guidelines for perioperative care after radical cystectomy 
for bladder cancer: Enhanced Recovery After Surgery (ERAS) society recommendations. Clin Nutr. 
2013; 32:879–87. [PubMed: 24189391] 
5. Furlong, C. Smoking cessation and its effects on outcomes of surgical interventions. http://
obesity.thehealthwell.info/node/27981
6. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z. Ad Hoc ESPEN Working Group. Nutritional risk 
screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 
2003; 22:321–36. [PubMed: 12765673] 
7. Hamilton-Reeves JM, Bechtel MD, Hand LK, et al. Effects of Immunonutrition for cystectomy on 
immune response and infection rates: A pilot randomized controlled clinical trial. Eur Urol. 2016; 
69:389–92. [PubMed: 26654125] 
8. Güenaga KF, Matos D, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal 
surgery. Cochrane Database Syst Rev. 2011; 7:CD001544.
9. Xu R, Zhao X, Zhong Z, Zhang L. No advantage is gained by preoperative bowel preparation in 
radical cystectomy and ileal conduit: a randomized controlled trial of 86 patients. Int Urol Nephrol. 
2010; 42:947–50. [PubMed: 20390354] 
10. Hashad MM, Atta M, Elabbady A, Elfiky S, Khattab A, Kotb A. Safety of no bowel preparation 
before ileal urinary diversion. BJU Int. 2012; 110:E1109–13. [PubMed: 23167296] 
11. Brady M, Kinn S, Stuart P. Preoperative fasting for adults to prevent perioperative complications. 
Cochrane Database Syst Rev. 2003:CD004423. [PubMed: 14584013] 
12. Smith I, Kranke P, Murat I, et al. Perioperative fasting in adults and children: guidelines from the 
European Society of Anaesthesiology. Eur J Anaesthesiol. 2011; 28:556–69. [PubMed: 21712716] 
13. Awad S, Varadhan KK, Ljungqvist O, Lobo DN. A meta-analysis of randomised controlled trials 
on preoperative oral carbohydrate treatment in elective surgery. Clin Nutr. 2013; 32:34–44. 
[PubMed: 23200124] 
14. Can MF, Yagci G, Dag B, et al. Preoperative administration of oral carbohydrate-rich solutions: 
comparison of glucometabolic responses and tolerability between patients with and without insulin 
resistance. Nutrition. 2009; 25:72–7. [PubMed: 18849145] 
15. Kauf TL, Svatek RS, Amiel G, et al. Alvimopan, a peripherally acting μ-opioid receptor antagonist, 
is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 
randomized, controlled trial. J Urol. 2014; 191:1721–7. [PubMed: 24342144] 
Azhar et al. Page 12
Eur Urol. Author manuscript; available in PMC 2017 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
16. Lee CT, Chang SS, Kamat AM, et al. Alvimopan accelerates gastrointestinal recovery after radical 
cystectomy: a multicenter randomized placebo-controlled trial. Eur Urol. 2014; 66:265–72. 
[PubMed: 24630419] 
17. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous 
thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002; 346:975–80. 
[PubMed: 11919306] 
18. Sachdeva A, Dalton M, Amaragiri SV, Lees T. Elastic compression stockings for prevention of 
deep vein thrombosis. Cochrane Database Syst Rev. 2010; 7:CD001484.
19. Kurz A, Sessler DI, Lenhardt R. Perioperative normothermia to reduce the incidence of surgical-
wound infection and shorten hospitalization. Study of wound infection and temperature group. N 
Engl J Med. 1996; 334:1209–15. [PubMed: 8606715] 
20. Maffezzini M, Campodonico F, Canepa G, Gerbi G, Parodi D. Current perioperative management 
of radical cystectomy with intestinal urinary reconstruction for muscle-invasive bladder cancer and 
reduction of the incidence of postoperative ileus. Surg Oncol. 2008; 17:41–8. [PubMed: 
17962014] 
21. Pruthi RS, Chun J, Richman M. Reducing time to oral diet and hospital discharge in patients 
undergoing radical cystectomy using a perioperative care plan. Urology. 2003; 62:661–5. 
[PubMed: 14550438] 
22. Daneshmand S, Ahmadi H, Schuckman AK, et al. Enhanced recovery protocol after radical 
cystectomy for bladder cancer. J Urol. 2014; 192:50–5. [PubMed: 24518775] 
23. Nix J, Smith A, Kurpad R, Nielsen ME, Wallen EM, Pruthi RS. Prospective randomized controlled 
trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic 
results. Eur Urol. 2010; 57:196–201. [PubMed: 19853987] 
24. Bochner BH, Dalbagni G, Sjoberg DD, et al. Comparing open radical cystectomy and robot-
assisted laparoscopic radical cystectomy: A randomized clinical trial. Eur Urol. 2015; 67:1042–50. 
[PubMed: 25496767] 
25. Novara G, Catto JW, Wilson T, et al. Systematic review and cumulative analysis of perioperative 
outcomes and complications after robot-assisted radical cystectomy. Eur Urol. 2015; 67:376–401. 
[PubMed: 25560798] 
26. Giglio MT, Marucci M, Testini M, Brienza N. Goal-directed hemodynamic therapy and 
gastrointestinal complications in major surgery: a meta-analysis of randomized controlled trials. Br 
J Anaesth. 2009; 103:637–46. [PubMed: 19837807] 
27. Bundgaard-Nielsen M, Secher NH, Kehlet H. “Liberal” vs. “restrictive” perioperative fluid 
therapy--a critical assessment of the evidence. Acta Anaesthesiol Scand. 2009; 53:843–51. 
[PubMed: 19519723] 
28. Wuethrich PY, Studer UE, Thalmann GN, Burkhard FC. Intraoperative continuous norepinephrine 
infusion combined with restrictive deferred hydration significantly reduces the need for blood 
transfusion in patients undergoing open radical cystectomy: results of a prospective randomized 
trial. Eur Urol. 2014; 66:352–60. [PubMed: 24012203] 
29. Donat SM, Slaton JW, Pisters LL, Swanson DA. Early nasogastric tube removal combined with 
metoclopramide after radical cystectomy and urinary diversion. J Urol. 1999; 162:1599–602. 
[PubMed: 10524876] 
30. Rao W, Zhang X, Zhang J, Yan R, Hu Z, Wang Q. The role of nasogastric tube in decompression 
after elective colon and rectum surgery: a meta-analysis. Int J Colorectal Dis. 2011; 26:423–9. 
[PubMed: 21107848] 
31. Mattei A, Birkhaeuser FD, Baermann C, Warncke SH, Studer UE. To stent or not to stent 
perioperatively the ureteroileal anastomosis of ileal orthotopic bladder substitutes and ileal 
conduits? Results of a prospective randomized trial. J Urol. 2008; 179:582–6. [PubMed: 
18078958] 
32. Pruthi RS, Nielsen M, Smith A, Nix J, Schultz H, Wallen EM. Fast track program in patients 
undergoing radical cystectomy: results in 362 consecutive patients. J Am Coll Surg. 2010; 210:93–
9. [PubMed: 20123338] 
33. Mukhtar S, Ayres BE, Issa R, Swinn MJ, Perry MJ. Challenging boundaries: an enhanced recovery 
program for radical cystectomy. Ann R Coll Surg Engl. 2013; 95:200–6. [PubMed: 23827292] 
Azhar et al. Page 13
Eur Urol. Author manuscript; available in PMC 2017 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
34. Arumainayagam N, McGrath J, Jefferson KP, Gillatt DA. Introduction of an enhanced recovery 
protocol for radical cystectomy. BJU Int. 2008; 101:698–701. [PubMed: 18190646] 
35. Hirose Y, Naiki T, Ando R, et al. Novel closing method using subcutaneous continuous drain for 
preventing surgical site infections in radical cystectomy. ISRN Urol. 2014; 2014:897451. 
[PubMed: 24734201] 
36. Roth B, Birkhäuser FD, Zehnder P, Burkhard FC, Thalmann GN, Studer UE. Readaptation of the 
peritoneum following extended pelvic lymphadenectomy and cystectomy has a significant 
beneficial impact on early postoperative recovery and complications: results of a prospective 
randomized trial. Euro Urol. 2011; 59:204–10.
37. López-Olaondo L, Carrascosa F, Pueyo FJ, Monedero P, Busto N, Sáez A. Combination of 
ondansetron and dexamethasone in the prophylaxis of postoperative nausea and vomiting. Br J 
Anaesth. 1996; 76:835–40. [PubMed: 8679359] 
38. Pillai P, McEleavy I, Gaughan M, et al. A double-blind randomized controlled clinical trial to 
assess the effect of Doppler optimized intraoperative fluid management on outcome following 
radical cystectomy. J Urol. 2011; 186:2201–6. [PubMed: 22014804] 
39. Traut U, Brügger L, Kunz R, et al. Systemic prokinetic pharmacologic treatment for postoperative 
adynamic ileus following abdominal surgery in adults. Cochrane Database Syst Rev. 
2008:CD004930. [PubMed: 18254064] 
40. Fitzgerald JE, Ahmed I. Systematic review and meta-analysis of chewing-gum therapy in the 
reduction of postoperative paralytic ileus following gastrointestinal surgery. World J Surg. 2009; 
33:2557–66. [PubMed: 19763686] 
41. Zingg U, Miskovic D, Pasternak I, Meyer P, Hamel CT, Metzger U. Effect of bisacodyl on 
postoperative bowel motility in elective colorectal surgery: a prospective, randomized trial. Int J 
Colorectal Dis. 2008; 23:1175–83. [PubMed: 18665373] 
42. Lewis SJ, Andersen HK, Thomas S. Early enteral nutrition within 24 h of intestinal surgery versus 
later commencement of feeding: a systematic review and meta-analysis. J Gastrointest Surg. 2009; 
13:569–75. [PubMed: 18629592] 
43. Klein S, Kinney J, Jeejeebhoy K, et al. Nutrition support in clinical practice: review of published 
data and recommendations for future research directions. Summary of a Conference Sponsored by 
the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and 
American Society for Clinical Nutrition. Am J Clin Nutr. 1997; 66:683–706. [PubMed: 9280194] 
44. Xu W, Daneshmand S, Bazargani ST, et al. Postoperative pain management after radical 
cystectomy: comparing traditional versus enhanced recovery protocol pathway. J Urol. 2015; 
194:1209–13. [PubMed: 26021824] 
45. Neville A, Lee L, Antonescu I, et al. Systematic review of outcomes used to evaluate enhanced 
recovery after surgery. Br J Surg. 2014; 101:159–70. [PubMed: 24469616] 
46. Karl A, Buchner A, Becker A, et al. A new concept for early recovery after surgery for patients 
undergoing radical cystectomy for bladder cancer: results of a prospective randomized study. J 
Urol. 2014; 191:335–40. [PubMed: 23968966] 
47. Stowers MD, Lemanu DP, Hill AG. Health economics in enhanced recovery after surgery 
programs. Can J Anaesth. 2015; 62:219–30. [PubMed: 25391739] 
48. Gregg JR, Cookson MS, Phillips S, et al. Effect of preoperative nutritional deficiency on mortality 
after radical cystectomy for bladder cancer. J Urol. 2011; 185:90–6. [PubMed: 21074802] 
49. Karl A, Rittler P, Buchner A, et al. Prospective assessment of malnutrition in urologic patients. 
Urology. 2009; 73:1072–6. [PubMed: 19232689] 
50. Large MC, Kiriluk KJ, DeCastro GJ, et al. The impact of mechanical bowel preparation on 
postoperative complications for patients undergoing cystectomy and urinary diversion. J Urol. 
2012; 188:1801–5. [PubMed: 22999697] 
51. Tabibi A, Simforoosh N, Basiri A, Ezzatnejad M, Abdi H, Farrokhi F. Bowel preparation versus no 
preparation before ileal urinary diversion. Urology. 2007; 70:654–8. [PubMed: 17991531] 
52. Aslan G, Baltaci S, Akdogan B, et al. A prospective randomized multicenter study of Turkish 
Society of Urooncology comparing two different mechanical bowel preparation methods for 
radical cystectomy. Urol Oncol. 2013; 31:664–70. [PubMed: 21546277] 
Azhar et al. Page 14
Eur Urol. Author manuscript; available in PMC 2017 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
53. Tobis S, Heinlen JE, Ruel N, et al. Effect of alvimopan on return of bowel function after robot-
assisted radical cystectomy. J Laparoendosc Adv Surg Tech A. 2014; 24:693–7. [PubMed: 
25180566] 
54. Lawrentschuk N, Colombo R, Hakenberg OW, et al. Prevention and management of complications 
following radical cystectomy for bladder cancer. Eur Urol. 2010; 57:983–1001. [PubMed: 
20227172] 
55. Kibel AS, Loughlin KR. Pathogenesis and prophylaxis of postoperative thromboembolic disease in 
urological pelvic surgery. J Urol. 1995; 153:1763–74. [PubMed: 7538597] 
56. Saar M, Ohlmann CH, Siemer S, et al. Fast-track rehabilitation after robot-assisted laparoscopic 
cystectomy accelerates postoperative recovery. BJU Int. 2013; 112:E99–106. [PubMed: 23145578] 
57. Dutton TJ, Daugherty MO, Mason RG, McGrath JS. Implementation of the Exeter enhanced 
recovery program for patients undergoing radical cystectomy. BJU Int. 2014; 113:719–25. 
[PubMed: 24712746] 
Azhar et al. Page 15
Eur Urol. Author manuscript; available in PMC 2017 July 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
*Take Home Message
The objective of this review was to provide an overview of the use and key elements of 
Enhanced Recovery after Surgery programs, which are multi-modal, multi-disciplinary 
care pathways that aim to optimize postoperative recovery. Additional objectives were to 
encourage the adoption of Enhanced Recovery after Surgery pathways and to identify 
needs for future clinical trials.
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Fig. 1. 
Selection process according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses statement.
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Table 2
Nutritional Risk Score 2002 scoring system [6]
(I) Score of the severity of disease
Score 1
General malignancy
Long-term hemodialysis
Chronic diseases (eg, cirrhosis and COPD)
Hip fracture
Diabetes
Score 2
Hematological malignancies
Major abdominal surgery
Severe pneumonia
Stroke
Score 3
Head and brain injury
Bone marrow transplant
Intensive care patients with an APACHE score higher than 10
(II) Score of the impaired nutrition status
Score 1 Weight loss > 5% in 3 mo or food intake below 50–75% of normal requirement in the preceding wk
Score 2 Weight loss > 5% in 2 mo or food intake below 25–50% of normal requirement in preceding week or BMI < 20.5, with poor general 
conditions
Score 3 Weight loss > 5% in preceding month or food intake below 25% of normal requirement in preceding week or BMI < 18.5, with poor general conditions
(III) Score of the age
Score 1 >70 yr
Nutrition risk screening score = Score of the severity of the disease + score of the impaired nutrition status + score of the age.
APACHE = Acute Physiology and Chronic Health Evaluation; BMI = body mass index; COPD = chronic obstructive pulmonary disease.
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